Macimorelin is FDA-approved as a one-dose test for adult GH deficiency

What is macimorelin approved for?

Macimorelin is approved for one job: a single 0.5 mg/kg oral dose used as a diagnostic test for adult growth hormone deficiency. The FDA approved it in December 2017 as a test, not a treatment ^[1]⁠^[8], and it is the only FDA-approved oral ghrelin-mimetic.

The dose provokes a GH pulse that clinicians measure over about 90 minutes to help distinguish deficient from normal pituitary function ^[1].

How does macimorelin trigger growth hormone release?

Macimorelin is an orally active agonist of the growth hormone secretagogue receptor (GHSR-1a), the same receptor endogenous ghrelin binds. A single oral dose stimulates pituitary somatotrophs to release growth hormone, producing a measurable peak in serum GH within roughly an hour.

That acute pulse is the entire clinical event macimorelin was built to produce. The pivotal trial gave macimorelin exactly once per test session, drew serum GH at fixed intervals, and compared the peak with a fixed diagnostic cutoff ^[1]. The study had no repeated-dosing arm. The mechanism is real and reproducible; what varies is what people do with that fact afterward.

How accurate is the macimorelin test?

The macimorelin test is accurate: at a 2.8 ng/mL cutoff, it showed 87% sensitivity and 96% specificity against the insulin tolerance test, the reference standard ^[1].

The 2018 validation trial was a multicenter, open-label, randomized, two-way crossover study, a solid design for establishing diagnostic accuracy ^[1]. It compared that macimorelin cutoff with an insulin tolerance test cutoff of 5.1 ng/mL. Negative agreement between the two tests was 95.38%, positive agreement was 74.32%, and macimorelin's own results reproduced 97% of the time on retest ^[1].

That strong diagnostic dataset is why professional consensus now lists macimorelin alongside the insulin tolerance test and the glucagon stimulation test as an accepted way to diagnose adult GH deficiency ^[4]⁠^[6].

Every GH stimulation test, macimorelin included, carries caveats: cutoffs vary by age, sex, and body mass index ^[7]. The glucagon test remains in use partly because macimorelin's cost limits access ^[5]. None of the diagnostic literature evaluates repeated macimorelin dosing for anything other than diagnostic reproducibility.

Does macimorelin's approval cover repeated dosing for muscle or fat loss?

Macimorelin's approval does not cover repeated dosing; the FDA and EMA reviewed a single oral dose as a test for adult GH deficiency ^[1]⁠^[8].

Regulators asked whether one dose produces a GH response accurate enough to help identify adult GH deficiency without the risks of the insulin tolerance test, which include severe hypoglycemia and contraindications in several patient groups ^[1]⁠^[8]. The trial answered that question, and the approval is scoped to it.

Nothing in the assessment addresses a second dose, a tenth dose, or daily dosing over months. No dataset reports chronic macimorelin dosing in humans for body composition, sleep, or recovery outcomes, because the drug has not been tested that way ^[1]⁠^[8].

Guideline bodies treat macimorelin strictly as a stimulation test, distinct from GH replacement therapy, a different drug class with its own trial evidence for metabolic and musculoskeletal outcomes ^[6]. Growth hormone's effects on body composition and strength have their own review. Macimorelin never entered that conversation as a treatment, because it was never studied as one.

What happened when anamorelin tested ghrelin agonism for chronic use?

Anamorelin, a ghrelin receptor agonist dosed daily instead of once, raised lean body mass in two phase 3 trials but missed its handgrip strength co-primary endpoint ^[2].

The trials, ROMANA 1 and ROMANA 2, enrolled patients with non-small-cell lung cancer and cachexia ^[2]. Over 12 weeks, lean body mass rose relative to placebo, but handgrip strength did not clear the bar needed alongside it ^[2].

Raising a body-composition surrogate was not enough; the functional outcome had to move too. The "FDA-approved ghrelin category" framing skips this result, which is the strongest evidence on what sustained ghrelin receptor agonism does. The anamorelin cachexia evidence has its own review.

What did the MK-677 study show about repeated dosing?

MK-677's GH response fell from a 55.9 mcg/L peak after one dose to 22.6 mcg/L with repeated daily dosing, in eight healthy men on a calorie-restricted diet ^[3].

The same 1998 study found that MK-677 improved short-term nitrogen balance during a controlled feeding protocol ^[3]. The decline from acute to chronic response is real and measured, in a tiny cohort over one week. It is not evidence of a durable anabolic effect at any scale that has been approved. MK-677's IGF-1 rise without functional gains covers the wider MK-677 record.

Does macimorelin's approval vouch for MK-677 and other ghrelin agonists?

Macimorelin's approval does not vouch for MK-677 or any other ghrelin agonist, because it covers one reliable, reproducible GH pulse for a lab test ^[1].

Anamorelin and MK-677, both formally tested for chronic, non-diagnostic outcomes, produced measurable hormone changes and then failed to clear an approval bar built around a functional endpoint ^[2]⁠^[3]. Macimorelin is the one exception that "succeeded," at a narrower task than the others attempted.

Marketing and forum claims about MK-677 and similar unapproved agents cite "raises GH and IGF-1" as their evidence. That phrase describes the same acute mechanism macimorelin is approved to trigger once, not a demonstrated downstream benefit.

A real receptor does not make chronic agonism at that receptor a proven benefit. The anamorelin and MK-677 data are the closest thing to a direct test of that question, and both fell short of it ^[2]⁠^[3]. The wider ghrelin agonist trial record shows what these drugs do change in people.

What is still unknown about chronic ghrelin receptor agonism?

Chronic macimorelin dosing has never been tested in humans for body composition, sleep, or recovery ^[1]⁠^[8], and three broader questions about the receptor class remain open:

• Long-term safety. No study has established the long-term safety of repeated dosing at the ghrelin receptor.
• Tachyphylaxis. None of the cited studies tracks response patterns beyond the one-week MK-677 data ^[3].
• Functional benefit. Whether any ghrelin receptor agonist could clear a functional endpoint at a different dose or in a different population has not been answered.